Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes

BACKGROUND: Eculizumab modifies the course of disease in patients with atypical haemolytic uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe are limited. METHODS: Patients enrolled in the Global aHUS Registry who received ≥1 month of eculizumab before discontinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ariceta, Gema, Fakhouri, Fadi, Sartz, Lisa, Miller, Benjamin, Nikolaou, Vasilis, Cohen, David, Siedlecki, Andrew M, Ardissino, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894930/
https://www.ncbi.nlm.nih.gov/pubmed/35261761
http://dx.doi.org/10.1093/ckj/sfab005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894930/
https://www.ncbi.nlm.nih.gov/pubmed/35261761
http://dx.doi.org/10.1093/ckj/sfab005

Ejemplares similares